NCT00148681已完成2 期
Preoperative Herceptin and Navelbine in Early Stage, HER-2 Positive Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 49
- 试验地点
- 3
- 主要终点
- To assess the complete response rate after preoperative herceptin and navelbine in HER-2 positive breast cancer.
研究概览
简要总结
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
详细描述
- As part of the patients pre-treatment evaluation, a clip will be placed within the tumor bed so that the surgeon can find it at the time of surgery. Four biopsies of the tumor will be obtained at the time of the clip placement for further testing at a later date.
- Depending upon the patient's risk level (as assessed by the treating physician), they will be treated similarly to one of two regimens. The first 8 months of both regimens are the same consisting of 12 weeks of herceptin and navelbine, followed by surgery and then 4 cycles of adriamycin and cytoxan. The treatment following these 8 months will depend upon the health risk to the patient and will be determined by both the patient and treating physician.
- Group 1: Lower Risk Regimen: Patients in this group will receive 3 phases of treatment. In Phase A they will receive Navelbine and Herceptin intravenously every week for 12 weeks. Upon completion of this therapy they will undergo surgery to remove the tumor. Following surgery there will be a 6 week recovery period where no treatment will be received. In Phase B, patients will receive adriamycin (doxorubicin) and cytoxan (cyclophosphamide) intravenously every 3 weeks for 12 weeks, for a total of 4 cycles. Patients then may or may not receive Phase C (depending upon physicians discretion), during which they will receive herceptin intravenously every 3 weeks for 40 weeks. If the physician decides that the patient needs radiation therapy, it will commence after the completion of adriamycin and cytoxan.
- Group 2: Higher Risk Regimen: Patients in this group will undergo four different phases of treatment. Phase A is identical to that of Group 1 (herceptin and navelbine for 12 weeks followed by surgery) as is Phase B (adriamycin and cytoxan every 3 weeks for 12 weeks for a total of 4 cycles). Phase C will consist of paclitaxel and herceptin weekly for a total of 12 weeks. If the physician decides that radiation therapy should be performed, it will commence within 6 weeks of the last dose of paclitaxel and herceptin. In Phase D, patients will receive herceptin intravenously every three weeks for 28 weeks.
- The following procedures and tests will be performed during this study: During Phase A: Every week: blood work; Every 3 weeks: physical exam, tumor assessment and bloodwork. During Phase B: Every 3 weeks; physical exam and blood work. At the start of Phase B and C: physical exam, EKG, MUGA scan or echocardiogram and bloodwork. During Phase C: Every 3 weeks for High risk patients and every 3 months for low risk patients; physical exam and blood work. End of Phase C: MUGA scan or echocardiogram. Phase C and D: every 3 months; physical exam, EGK, MUGA scan or echocardiogram and bloodwork.
- At the end of the study patients will undergo a physical exam, EKG, MUGA scan or echocardiogram and bloodwork.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •EGOG performance status of 0-1
- •HER2 overexpressing (IHC 3+ or FISH +)
- •Stage II or III breast cancer. Clinical T1N1M) and inflammatory (T4) breast cancer are eligible
- •Patients with metastatic breast cancer (Stage IV) which is limited to supraclavicular and/or infraclavicular node positivity are eligible
- •18 years of age or older
排除标准
- •Prior therapy with herceptin, paclitaxel or other taxane, doxorubicin or other anthracycline-type chemotherapy, navelbine
- •Pregnant or lactating women
- •Uncontrolled infections, including AIDS
- •History or symptoms diagnostic of systemic connective tissue or inflammatory disease
- •Active or severe cardiovascular or pulmonary disease, including recent myocardial infarction or deep-venous thrombosis/pulmonary embolism, congestive heart failure, uncontrolled hypertension, or steroid-dependent asthma.
- •Left ventricular ejection fraction < 50%
- •Peripheral neuropathy of any etiology that exceeds grade 1
- •Prior history of malignancy treated without curative intent
- •Uncontrolled diabetes
研究组 & 干预措施
Higher Risk Regimen
Experimental
干预措施: Paclitaxel (Drug)
Lower Risk Regimen
Experimental
干预措施: Herceptin (Drug)
Lower Risk Regimen
Experimental
干预措施: Navelbine (Drug)
Lower Risk Regimen
Experimental
干预措施: Doxorubicin (Drug)
Lower Risk Regimen
Experimental
干预措施: Cyclophosphamide (Drug)
Higher Risk Regimen
Experimental
干预措施: Herceptin (Drug)
Higher Risk Regimen
Experimental
干预措施: Navelbine (Drug)
Higher Risk Regimen
Experimental
干预措施: Doxorubicin (Drug)
Higher Risk Regimen
Experimental
干预措施: Cyclophosphamide (Drug)
结局指标
主要结局
To assess the complete response rate after preoperative herceptin and navelbine in HER-2 positive breast cancer.
时间窗: 2 years
次要结局
- To determine the safety of herceptin and navelbine in this patient population (either high risk or low risk).(2 years)
研究者
Eric P Winer, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast CancerBreast CancerNCT00148668Eric Winer, MD81
已完成
2 期
Neoadjuvant Therapy With Herceptin and Taxol for Breast CancerBreast CancerNCT00136539Harold J. Burstein, MD, PhD41
招募中
不适用
Pre-operative Therapy in Breast CancerBreast CancerNCT05621564RenJi Hospital6,032
已完成
4 期
Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic FloorPelvic Organ ProlapseMenopauseNCT01778985University of Texas Southwestern Medical Center30
已完成
1 期
Capecitabine and Lenvatinib With External Radiation in Rectal AdenocarcinomaRectal CancerRectal AdenocarcinomaNCT02935309H. Lee Moffitt Cancer Center and Research Institute20